Amneal Pharmaceuticals' (AMRX) shares rose nearly 10% in recent Monday trading after JPMorgan upgraded the stock to overweight from neutral and adjusted its price target to $12 from $9.
The drugmaker said last week that it is set to launch mesalamine 800-milligram delayed-release tablets to treat moderately active ulcerative colitis in adults. The company added it had received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.
Trading volume stood at about 2.4 million shares against a daily average of more than 1.1 million shares.
Price: 8.60, Change: +0.77, Percent Change: +9.77
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.